Compare BRFH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | CVM |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.6M | 32.4M |
| IPO Year | 2010 | 1996 |
| Metric | BRFH | CVM |
|---|---|---|
| Price | $2.71 | $3.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 35.8K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.52 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $211,467.00 | ★ $264,033.00 |
| Revenue This Year | $37.56 | N/A |
| Revenue Next Year | $101.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 92.09 | 65.45 |
| 52 Week Low | $2.00 | $0.18 |
| 52 Week High | $6.08 | $13.48 |
| Indicator | BRFH | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 30.83 |
| Support Level | $2.55 | $2.02 |
| Resistance Level | $3.47 | $6.75 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.01 | 3.49 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.